British researchers have concluded that a Swiss echinacea extract is both safe and effective in helping to prevent symptoms of the common cold, according to a study published in American Botanical Council's peer-reviewed journal HerbalGram.
An experimental drug therapy under development by Novartis for liver transplant patients appears to provide similar efficacy and better kidney function, compared with a drug made by Astellas Pharma, according to results of a late-stage clinical trial.
A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.
An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.
It’s been cited as one of the biggest health crises facing the United States and, if solved, the equivalent dollar value of a blockbuster drug. According to the latest statistics from pharmacy benefit manager Express Scripts, poor medication adherence costs the country $317 billion per year, an upgrade from the $290 billion calculated in a study released in 2009 by the New England Healthcare Institute.
Cellceutix on Wednesday reported that the Food and Drug Administration granted a section 505(b) designation for its Prurisol treatment for psoriasis, which would allow the company to forgo early-stage trials and advance Prurisol into latter-stage clinical trials.
An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.
Adherence interventions targeted to nonadherent patients proved more effective in improving medication adherence when compared with broad interventions that cast a wide net to encompass all medication takers, according to new research sponsored by CVS Caremark.
The $317 billion problem of medication nonadherence has many sources that often combine and overlap in complex ways. But fears of whether a drug is safe and will work are among of the most frequently cited reasons why patients don't take their drugs as prescribed, or don't take them at all.
Drug maker Apricus Biosciences will receive regulatory guidance from the Food and Drug Administration in July that will contain feedback concerning the drug maker's plans to seek approval for a nail fungus treatment.
An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.